Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

37 recalls, newest first

Class III · Low risk

Hydrocortisone 1% & Acetic Acid 2% Otic Solution

Failed Impurities/Degradation Specifications: Out-of-specification results obtained for related impurities and slightly lower than the established level of the Hydrocortisone Assay obtained during stability testing.

Completed Impurity / degradation Taro Pharmaceuticals U.S.A., Inc. NDC 51672-3007-01 D-0633-2024
Class III · Low risk

Methotrexate Tablets

Presence of Foreign Tablets: Potential presence of Fludrocortisone Acetate Tablet USP 0.1 mg within the Methotrexate 2.5 mg 100-count Bottle.

Completed Particulate / foreign matter Amneal Pharmaceuticals, LLC NDC 69238-1423-1 D-0629-2024
Class II · Moderate risk

Phenazopyridine HCl Tablets USP

Product Mix Up. A bottle of Phenazopyridine HCl tablets USP 100 mg contained Phenobarbital tablets 16.2 mg.

Completed Other Winder Laboratories, LLC NDC 75826-114-10 D-0545-2024
Class II · Moderate risk

Cardura XL

Failed Impurities/Degradation Specifications

Completed Impurity / degradation Viatris Inc NDC 0049-2080-10 D-0603-2024
Class II · Moderate risk

Cardura XL

Failed Impurities/Degradation Specifications

Completed Impurity / degradation Viatris Inc NDC 0049-2040-10 D-0602-2024
Class III · Low risk

Valacyclovir Tablets USP

Failed Tablet/Capsule Specifications: There is a potential for the imprint, M 122, to be missing on some tablets.

Completed Failed specification Viatris Inc NDC 0378-4275-77 D-0481-2024
Class II · Moderate risk

Gordofilm Wart Remover

cGMP Deviations

Completed cGMP deviation Dercher Enterprises, Inc., DBA Gordon Laboratories NDC 10481-3009-01 D-0495-2024
Class II · Moderate risk

S.P Labs

Failed Stability Specifications

Completed Stability / shelf life Specialty Process Labs LLC D-0447-2024
Class II · Moderate risk

S.P.Labs

Failed Stability Specifications

Completed Stability / shelf life Specialty Process Labs LLC NDC 81305-500-01 D-0446-2024
Class II · Moderate risk

Fexofenadine Hydrochloride Tablets

CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.

Completed Microbial contamination Sun Pharmaceutical Industries INC NDC 51660-998-30 D-0273-2024

Recalls by year